Mostrar el registro sencillo del ítem

Evaluation of commercial myxomatosis vaccines against recombinant myxoma virus (ha-MYXV) in Iberian hare and wild rabbit

dc.contributor.authorDos Santos, Fabio A. Abade
dc.contributor.authorCarvalho, Carina L.
dc.contributor.authorValente, Pâmela C. L. G.
dc.contributor.authorCalonge Sanz, Inés 
dc.contributor.authorDalton, Kevin Paul 
dc.contributor.authorParra Fernández, José Francisco 
dc.date.accessioned2022-09-23T11:17:38Z
dc.date.available2022-09-23T11:17:38Z
dc.date.issued2022
dc.identifier.citationVaccines, 10(3) (2022); doi:10.3390/vaccines10030356
dc.identifier.issn2076-393X
dc.identifier.urihttp://hdl.handle.net/10651/64808
dc.description.sponsorshipFranscisco Parra's laboratory was funded by grant AGL2017-83395-R from the Spanish Ministerio de Ciencia Innovación y Universidades, cofinanced by FEDER. KPD acknowledges funding from the Spanish Ministry for Science Innovation and Universities cofinanced by FEDER (reference number PID2020-120349RB-100).spa
dc.description.statementofresponsibilityDos Santos FAA , Carvalho CL, Valente PCLG, Armés H, Reemers SS, Peleteiro MC, Calonge Sanz I, Dalton KP, Parra F, Duarte MD
dc.language.isoengspa
dc.relation.ispartofVaccines, 10(3)spa
dc.rightsAtribución 4.0 Internacional*
dc.rights© 2022 Los autores
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleEvaluation of commercial myxomatosis vaccines against recombinant myxoma virus (ha-MYXV) in Iberian hare and wild rabbitspa
dc.typejournal articlespa
dc.identifier.doi10.3390/vaccines10030356
dc.relation.projectIDMCIU/FEDER/AGL2017-83395-Rspa
dc.relation.projectIDMCIU/FEDER/PID2020-120349RB-100spa
dc.relation.publisherversionhttp://doi.org/10.3390/vaccines10030356spa
dc.rights.accessRightsopen accessspa
dc.type.hasVersionVoR


Ficheros en el ítem

untranslated

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este ítem está sujeto a una licencia Creative Commons